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-Conotoxins are small peptide inhibitors ofmuscle andneuro-
nal tetrodotoxin (TTX)-sensitive voltage-gated sodium channels
(VGSCs). Here we report the isolation of -conotoxins SIIIA and
SIIIB by 125I-TIIIA-guided fractionation of milked Conus striatus
venom. SIIIA and SIIIB potently displaced 125I-TIIIA from native
rat brainNav1.2 (IC50 values 10 and 5 nM, respectively) andmuscle
Nav1.4 (IC50 values 60 and 3 nM, respectively) VGSCs, and both
inhibited current through Xenopus oocyte-expressed Nav1.2 and
Nav1.4. An alanine scan of SIIIA-(2–20), a pyroglutamate-trun-
cated analogue with enhanced neuronal activity, revealed residues
important for affinity and selectivity. Alanine replacement of the
solvent-exposed Trp-12, Arg-14, His-16, Arg-18 resulted in large
reductions in SIIIA-(2–20) affinity, with His-16 replacement
affecting structure. In contrast, [D15A]SIIIA-(2–20) had signifi-
cantly enhanced neuronal affinity (IC50 0.65 nM), while the double
mutant [D15A/H16R]SIIIA-(2–20) showed greatest Nav1.2 versus
1.4 selectivity (136-fold). 1H NMR studies revealed that SIIIA
adopted a single conformation in solution comprising a series of
turnsandan-helicalmotifacrossresidues11–16that isnot found
in larger -conotoxins. The structure of SIIIA provides a new
structural template for the development of neuronally selective
inhibitors of TTX-sensitive VGSCs based on the smaller -cono-
toxin pharmacophore.
Voltage-gated sodium channels (VGSC)3 are crucial for the
excitability of nerve and muscle cells (1). Nine different VGSC
isoforms (Nav1.1–1.9) have been identified and characterized
as either tetrodotoxin-sensitive (TTX-S) or tetrodotoxin-resis-
tant (TTX-R) (2, 3). Of these isoforms, the TTX-R Nav1.8 and
1.9 are implicated in neuropathic pain states (4, 5), the TTX-S
Nav1.7 is implicated in allodynia and neuropathic pain (6–10),
and theTTX-SNav1.3 is up-regulated in inflammatory pain (5).
To learn more about the different roles played by each of the
VGSC subtypes in normal and disease states requires new
inhibitors with improved VGSC subtype selectivity.
Inhibitors of TTX-S VGSCs include tetrodotoxin (TTX)
from puffer fish, the saxitoxins (STXs) frommarine dinoflagel-
lates, and the -conotoxins from the venom of cone snails.
These toxins act competitively at Site 1 in the P-loop region of
the ion-conducting pore of the -subunit of the VGSC (3, 11).
While TTX and STX act with nanomolar potency across the six
TTX-S VGSCs (Nav1.1–1.4, 1.6, and 1.7), -conotoxins are
more discriminating. Currently 12 -conotoxins have been
identified from nine species of fish hunting cone snails (Table
1). -Conotoxins GIIIA, GIIIB, and GIIIC from Conus geogra-
phus selectively target the skeletal muscle Nav1.4, PIIIA from
Conus purpurasence (12–14) and TIIIA fromConus tulipa (15)
target Nav1.2 and 1.4, and -conotoxins SmIIIA from
Conus stercusmuscsarum (16, 17), SIIIA from Conus striatus
(18, 19), andKIIIA fromConus kinoshitai (18) target amphibian
TTX-R sodium channels. More recently, KIIIA has also been
shown to inhibit TTX-S sodium channels in mouse DRG and
rat TTX-S sodium channels expressed inXenopus oocytes (20).
Lastly,-conotoxinsCnIIIA,CnIIIB fromConus consors, CIIIA
fromConus catus, andMIIIA fromConus maguswere found to
inhibit TTX-R and TTX-S sodium channels in frog DRG but
not rat ormouse DRGneurons (21).Most reported-conotox-
ins have a conserved arginine in loop 2, which is essential for
high affinity interactions at TTX-S sodium channels (15,
22–25). In contrast, SIIIA and KIIIA have a much shorter loop
2 and a lysine instead of an arginine in the corresponding posi-
tion. Recent structure-activity studies on TIIIA (15) and KIIIA
(20) have confirmed that the arginine in loop 2 is crucial for
TIIIA affinity at both neuronal and skeletal muscle sodium
channels, whereas the structurally equivalent lysine was only
important for affinity at the skeletal muscle VGSC. Three-di-
mensional structures of -conotoxins GIIIA, GIIIB, PIIIA,
TIIIA, and SmIIIA have been determined by NMR (14, 15, 17,
26, 27). These structures reveal a similar fold for the -cono-
toxins despite high sequence divergence. At present, structures
of-conotoxins SIIIA andKIIIA aremodeled from SmIIIA (18,
20, 21).
This study reports the isolation and structure-activity of
-conotoxins SIIIA and SIIIB from the milked venom of
C. striatus. To define aspects of their structure that contribute
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to binding to mammalian VGSCs, we determined the NMR
structure of SIIIA. Distinct from other -conotoxins, SIIIA
adopts a single conformation in solution that includes an-hel-
ical motif not previously seen in other members of this class.
This structural change was associated with a significant phar-
macophore shift from the dominant arginine residue in loop 2
of the larger-conotoxins to a series of five similarly important
residues, including four associated with the -helical region, in
the smaller SIIIA. Interestingly, a number of SIIIA analogues
had significantly enhanced neuronal selectivity, opening the
way to the development of subtype-selective neuronal VGSC
inhibitors.
EXPERIMENTAL PROCEDURES
Isolation of -Conotoxins SIIIA and SIIIB—Crude C. striatus
milked venom was separated into 80 1-min fractions by semi-
preparative RP-HPLC using a Vydac C18 column (250  10
mm, 5) eluted at 3ml/min with a 1% gradient from 100%A to
80%B over 80min (solvent A 0.05% trifluoroacetic acid, solvent
B 90% ACN  0.045% trifluoroacetic acid). The eluant was
monitored at 230 nm and 125I-TIIIA-guided fractionation (15)
of the crude milked venom RP-HPLC fractions of C. striatus
used to isolate SIIIA and SIIIB to homogeneity. The sequences
of SIIIA and SIIIB (Table 1) were determined by Edman
sequencing only after pyroglutamate aminopeptidase diges-
tion, indicating that the N-terminal residue of both these cono-
toxins was a pyroglutamate. The observed masses for native
SIIIA and SIIIB (2206.8 and 2120.7 Da, respectively) were con-
sistent with the Edman sequencing results for peptides with an
amidated C terminus. Co-injected synthetic and native SIIIA
and SIIIB (2:1 ratio) co-eluted on a Vydac C18 reversed-phase
HPLC column (250  4.6 mm, 5 ) eluted with a 1% gradient
from 100% A to 50% B over 50 min, confirming the identity of
the native peptides.
Peptide Synthesis—-Conotoxins SIIIA and SIIIB and ana-
logues were prepared by Boc chemistry (28) using methods
described previously (14). Side-chain protecting groups chosen
were Arg(Tos), Asp(OcHex), Lys(CIZ), Ser(Bzl), Asn(Xan),
His(DNP), and Cys(p-MeBzl). The crude reduced peptides
were purified by preparative RP-HPLC using a 1% gradient
(100% A to 80% B over 80 min) and UV monitoring (230 nm),
and oxidized at 0.02 mM in either aqueous 0.33 M NH4OAc/0.5
MGnHCl/2MNH4OH, or 100 mM ammonium bicarbonate in
the presence of oxidized and reduced glutathione (29). Oxi-
dized peptideswere purified by preparative RP-HPLC. Peptides
were quantified initially by triplicate amino acid analysis to cre-
ate an external reference standard for HPLC quantitation of
each peptide (30). Mass spectra were acquired on a PE-Sciex
API III triple quadrupole electrospray mass spectrometer in
positive ion mode (m/z 500–2000 at 0.1–0.2 Da steps, declus-
tering potentials of 10–90V, and dwell times of 0.4–1.0 s). Data
were deconvoluted using MacSpec 3.2 (Sciex, Canada) to
obtain themolecular weight from themultiply charged ion spe-
cies. Mass spectrometry was used to confirm purity and to
monitor peptide oxidation (data not shown).
Chemicals and Reagents—Acetonitrile, methanol, ethanol,
and glacial acetic acid were from BDH (Poole, UK). Phenyl iso-
thiocyanate and amino acid standards were from Pierce.
HBTU, dimethyl formamide, dichloromethane, trifluoroacetic
acid, N,N-diisopropylethylamine, dicyclohexylcarbodiimide,
and 1-hydroxybenzotriazole were all peptide synthesis grade
from Auspep (Melbourne, Australia). p-Methylbenzhy-
drylamine 1% cross-linked divinylbenzene polystyrene resin
was from the Peptide Institute (Osaka, Japan), and BocPAM-
Phe resin was from Applied Biosystems (Fosters City, CA).
Purified water was obtained from a tandem Milli-RO/Milli-Q
system (Bedford, MA). p-Cresol, p-thiocresol, guanidineHCl
(99%), reduced and oxidized glutathione, and triethylamine
(freshly distilled) were from Sigma Aldrich. Anhydrous hydro-
gen fluoride (HF) was supplied by BOC Gases (Brisbane, Aus-
tralia). Ammonium acetate (AR) and ammonium sulfate (AR)
was from Ajax Chemicals (Australia). Boc-L-amino acids were
purchased from Bachem and Novabiochem (La Jolla, CA). All
other reagents and solvents were ACS analytical reagent grade.
Radioligand Binding Studies—125I-TIIIA (prepared using
IODOGEN) radioligand binding studies were performed using
rat brain and rat skeletal muscle preparations to measure
Nav1.2 and Nav1.4 affinity, as previously described (15). Non-
linear regressions (Hillslope-1) were fitted to triplicate data
obtained for each experiment using Prism software (GraphPad,
San Diego, CA).
Recording of Depolarization-activated Sodium Ion Currents
in Rat DRG Neurons—Neonatal rat DRG neurons were pre-
pared as described previously (31). Whole cell TTX-S and
TTX-R sodium ion currents were recorded in using an Axo-
patch 200A patch clamp amplifier (Molecular Devices Corp.).
Series resistance was routinely compensated by 70–80%.
Capacitive and leakage currents were digitally subtracted using
a P/6 pulse protocol. Internal pipette solution contained (in
mM): NaCl 10, CsF 130, CsCl 10, EGTA 10, HEPES-CsOH 10,
pH 7.2, 290–300 mOsM (with sucrose). The bath solution con-
tained (in mM): NaCl 50, KCl 5, MgCl2 1, CaCl2 1, glucose 10,
tetraethylammonium (TEA)-Cl 90, HEPES-TEA-OH 10, pH
7.35. TTX-resistant sodium ion currents were recorded from
small DRG neurons (25 m diameter) in the presence of 300
nM TTX. Large neurons (40 m diameter), in which the
sodium ion current exhibited fast activation and inactivation
kinetics and was mostly TTX-sensitive (90%), were used to
study toxin effects onTTX-S sodium ion current after complete
washout of TTX block. Toxins were diluted in extracellular
solution and added via a gravity-fed perfusion system.
Xenopus Oocyte Experiments—Depolarization-activated
sodium ion currents were recorded from Xenopus oocytes
expressing various VGSC -subunit subtypes using a two-elec-
trode (virtual ground circuit) voltage clamp at room tempera-
ture (20–23 °C) with a GeneClamp 500B amplifier and
pCLAMP 8 software (Axon Instruments Inc, Union City, CA).
Bath solution contained (in mM) 100 NaCl, 2 KCl, 1 MgCl2, 0.3
CaCl2, and 20 HEPES-NaOH, pH 7.5. Data were low pass-fil-
tered at 2 kHz, digitized at 10 kHz, and leak-subtracted on-line
using a P/6 protocol and analyzed off-line. Data were ana-
lyzed using Clampfit 8 software (Axon Instruments Inc., Union
City, CA). Rat Nav1.2 and rat Nav1.3 was a gift from A. Goldin
(University of California), human Nav1.5 a gift from R. Kass
(Columbia University), and human Nav1.7 a gift from N. Klug-
bauer (TeknischenUniversita¨t,Munich). Toxinswere added by
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direct bath application (static bath) followed by extensive mix-
ing to reach the final concentrations stated. The steady-state
blockwas reached after8min of toxin exposure, andwashout
of SIIIA was followed for 20–30 min.
1H Nuclear Magnetic Resonance (NMR) Spectroscopy—All
NMR experiments were recorded on a Bruker ARX 500 spec-
trometer equipped with a z-gradient unit, a Bruker DMX 750,
or a Bruker 600 Avance spectrometer equipped with a x,y,z-
gradient unit. Peptide concentrations were 2 mM. SIIIA and
SIIIB were examined in 95%H2O/5% D2O (pH 3.0, 275–298 K)
and in 100%D2O (260–293 K). SIIIA analogues were examined
in 90%H2O/10%D2O, pH 3.0. For SIIIA, 1HNMR experiments
recorded included NOESY, (mixing times 120, 300, and 400
ms), TOCSY (mixing time 80 ms), double-quantum filtered
(DQF)-COSY, and E-COSY in 100% D2O. Slowly exchanging
amide protons were detected by acquiring one-dimensional
NMR spectra immediately after dissolving the peptide in 100%
D2O at pH 3.5. For all other analogues, TOCSY experiments
with a mixing time of 80 ms were acquired. Additional NOESY
experiments were only run if ambiguities arose during assign-
ment. All spectra were run over 6024 Hz (500 MHz), 7184 Hz
(600 MHz), or 8192 Hz (750 MHz) with 4K data points, 400–
512 FIDs, 8–64 scans, and a recycle delay of 1–2 s. The solvent
was suppressed using the WATERGATE sequence (32). Spec-
tra were processed using UXNMR as described previously (29)
and using Aurelia, subtraction of background was used to min-
imize T1-noise. Chemical shift values of SIIIA and analogues
were obtained in 90% H2O, 10% D2O and referenced internally
to DSS at 0.00 ppm. Secondary H shifts were measured and
compared with values for random coil shifts (33).
SIIIA was assigned in sparky (34), and distance informa-
tion obtained by integration of a 300 ms mixing time NOESY
spectrum. Backbone dihedral restraints were derived from
3JHN-Hcoupling constants from a DQF-COSY spectrum or a
one-dimensional 1H NMR spectrum. The  dihedral angle
restraints included were restrained to 120 30° for 3JHN-H8
Hz and60 30° for 3JHN-H5.8Hz. 1 dihedral angels were
determined from intraresidue nuclearOverhauser effect (NOE)
and 3JH-H coupling patterns for an E-COSY spectrum. Initial
structures were generated using dyana (35), and final structures
were calculated in explicit water with CNS (36) as previously
described (37). An initial 50 structures were calculated, and the
17 lowest overall energy structures selected to represent the
solution structure of SIIIA.
RESULTS
Isolation of -Conotoxins SIIIA and SIIIB—To identify
-conotoxins selective for neuronal VGSCs, fractionated
milked C. striatus venom was assayed for the ability to displace
125I-TIIIA from rat brain sodium channels (15). Three active
fractionswith retention times of 20, 21, and 24min (Fig. 1) were
purified to homogeneity, digested using pyroglutaminase, and
Edman-sequenced to reveal three peptides with a CC-C-C-CC
motif characteristic of -conotoxins (38). Fraction 24 con-
tained the sequence of TIIIA, previously identified in C. tulipa
by PCR (15), fraction 20 the sequence for SIIIA, while fraction
21 contained a sequence for a new-conotoxinwe named SIIIB
(Table 1). SIIIA and SIIIB each comprised 20 residueswith a net
charge of2 and3, respectively. Mass spectrometry and co-
elution studies of the native and synthetic peptides confirmed
the sequences and C-terminal amidation of both peptides (data
not shown).
Radioligand Binding Studies—Synthetic -conotoxin SIIIA
and SIIIB each potently displaced 125I-TIIIA fromVGSCs in rat
brain and rat skeletal muscle (Fig. 2). The pIC50values for SIIIA
and SIIIB and selected additional -conotoxins are summa-
rized in Table 2. Similar to TTX and STX, SIIIA had a small but
FIGURE 1. Identification of native SIIIA and SIIIB in milked crude C. stria-
tus venom. Active fractions eluting from RP-HPLC using a 1% gradient
(0–80% B solvent B: 90% ACN, 0.045% trifluoroacetic acid) displaced 125I-
TIIIA-(2–22) binding to rat brain. Dashed line indicates non-specific binding,
and inset shows Conus striatus venom being collected by milking.
TABLE 1
-Conotoxin sequences and VGSC selectivity
Z, Pyroglutamate; O, hydroxyproline.
Peptidea Sequence Selectivity Ref.
SIIIB ZN–CCNG--GCSSKWCKGHARCCb 1.4 1.2 This work
SIIIA ZN–CCNG--GCSSKWCRDHARCCb 1.2 1.4 This work (18, 19)
KIIIA ---CCN----CSSKWCRDHSRCCb 1.2 1.4 (18, 20)
SmIIIA ZR—CCNGRRGCSSRWCRDHSRCCb Amphibian (16)
MIIIA Z—GCCNVPNGCSGRWCRDHAQCCb Amphibian (21)
CIIIA –GRCCEGPNGCSSRWCKDHARCCb Amphibian (21)
CnIIIA –GRCCDVPNACS-RWCRDHAQCCb Amphibian (21)
CnIIIB Z—GCCGEPNLCFTRWCRNNARCCRQQc Amphibian (21)
TIIIA RHGCCKGOKGCSSRECRO-QHCCb 1.4 1.2 (15)
PIIIA ZRLCCGFOKSCRSRQCKO-HRCCb 1.4 1.2 (24)
GIIIA RD-CCTOOKKCKDRQCKO-QRCCAb 1.41.2 (38)
GIIIB RD-CCTOORKCKDRRCKO-MKCCAb 1.4 1.2 (38)
GIIIC RD-CCTOOKKCKDRRCKO-LKCCAb 1.4 1.2 (38)
a SIIIA, SIIIB, and KIIIA are smaller -conotoxins, whereas the others are defined as larger -conotoxins.
b C-terminal amidation.
c Free acid C-terminal. Cysteines 1–4, 2–5, 3–6 are paired.
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significant preference for neuronal Nav1.2 over the skeletal
muscle Nav1.4, whereas SIIIB had a preference for Nav1.4. Both
SIIIA and SIIIB were full inhibitors of 125I-TIIIA binding to rat
brain or skeletalmuscle sodium channels. Interestingly, remov-
ing the pyroglutamate residue at the N terminus (SIIIA-(2–20)
and SIIIB-(2–20)) enhanced SIIIA and decreased SIIIB activity
at Nav1.2, while the reverse effect was observed at Nav1.4 (Fig.
4). These shifts in potency made SIIIA-(2–20) more Nav1.2-
selective and SIIIB-(2–20) more Nav1.4-selective. Like TIIIA,
SIIIA was unable to fully displace [3H]STX from rat brain (data
not shown) suggesting selectivity for Nav1.2 over other TTX-S
sodium channels. All displacement curves were best fitted with
a Hill slope of1.
Effects of SIIIA on Whole Cell Sodium Ion Currents—The
effects of -conotoxin SIIIA was investigated on both TTX-S
and TTX-R sodium ion current in neonatal rat DRG (31). SIIIA
at 3 M produced no detectable inhibition of either TTX-S or
TTX-R sodium ion currents in rat DRG neurons (data not
shown).
Effects of -Conotoxins on Oocyte-expressed VGSC Subtypes—
SIIIA was examined for inhibition of sodium ion current
throughVGSC subtypes expressed inXenopus oocytes. SIIIA at
3M caused 95% inhibition ofNav1.2 current, 45% inhibition of
Nav1.3 current (Fig. 3A), but no detectable inhibition of sodium
ion current throughNav1.5,Nav1.7, orNav1.8 (data not shown).
The IC50 values for SIIIA was 790 nM (95% CI 630–990 nM) at
Nav1.2, 330 nM (95% CI 300–360 nM) at Nav1.4, and 5.3 M
(95% CI 3.6–7.6 M) at Nav1.3 (Fig. 3B). SIIIB at 3 M caused
93% inhibition of Nav1.2 current and 10% inhibition of Nav1.7
current (data not shown) but was not tested on other VGSC
subtypes. The inhibitory effect of SIIIA was not reversed upon
washout (Fig. 3C), in contrast to TIIIA which was fully reversi-
ble upon washout at Nav1.2 (15).
Affinity of -Conotoxin Analogues—The affinity of -cono-
toxin analogues of SIIIA and SIIIB are shown in Fig. 4. SIIIA-
(2–20) had decreased affinity at Nav1.4, but increased binding
affinity at Nav1.2 sodium channel, whereas SIIIB-(2–20) had
increased affinity at both subtypes. In an attempt to identify
residues contributing to the neuronal selectivity, we produced
an alanine scan of SIIIA-(2–20), except for the small Asn, Gly,
and Ser residues in loops 1 and 2. Surprisingly, [K11A]SIIIA-
FIGURE 2. Displacement of 125I-TIIIA from (A) rat brain Nav1.2 and (B) rat skel-
etal muscle Nav1.4 VGSCs by SIIIA (), SIIIB (f), and selected SIIIA analogues,
SIIIA-(2–20) () [D15A]SIIIA-(2–20) (), and [R11,A15]SIIIA-(2–20) (), as well
as TIIIA for comparison (ƒ).
TABLE 2
-Conotoxin affinity (pIC50 S.E.) determined from displacement
of 125I-TIIIA from rat brain and skeletal muscle sodium channels
(n>3)
-Conotoxin Brain (Nav1.2) Muscle (Nav1.4) Selectivitya
SIIIA 8.02 0.12 7.67 0.13 0.35
SIIIB 8.29 0.15 8.49 0.11 –0.20
TIIIA 9.27 0.06 9.72 0.08 –0.45
PIIIA 8.72 0.07 9.05 0.05 –0.33
GIIIA 6.47 0.27 10.0 0.05 –3.53
GIIIB 7.85 0.15 10.0 0.05 –2.15
GIIIC 6.34 0.16 10.0 0.05 –3.62
STX 9.35 0.05 8.90 0.06 0.45
TTX 8.16 0.21 7.32 0.18 0.84
aNeuronal selectivity calculated as brain pIC50muscle pIC50.
FIGURE3. Inhibitionof recombinantVGSCsexpressed inXenopusoocytes
by-conotoxin SIIIA.A, superimposeddepolarization-activated sodium ion
currentsmediated byNav1.2, Nav1.3, andNav1.4 in the absence andpresence
of 1MSIIIA. Oocyteswere held at80mVanddepolarized to 0mVevery 5 s.
B, concentration-response curves obtained for SIIIA inhibition of Nav1.2,
Nav1.3, and Nav1.4 (n 	 3–5). C, kinetics of SIIIA inhibition of Nav1.2. The
on-rate curve was fitted with a single exponential function, yielding a on of
4.0 min for 3M SIIIA. Inhibition was not reversed upon washout for up to 30
min (n	 3 S.E.).
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(2–20) had only a small 6-fold reduction in affinity at Nav1.2
and Nav1.4, compared with the 100–300-fold reduction in
affinity for the equivalent substitution inTIIIA ([R14A]TIIIA at
rat Nav1.2) (15) and GIIIA ([R13A]GIIIA at rat Nav1.4) (39). In
contrast, the adjacentmutant [W12A]SIIIA-(2–20) had 22- and
87-fold reduced affinity compared with SIIIA-(2–20) at Nav1.2
andNav1.4, respectively, similar to that reported for KIIIA (20).
Removing the negative charge at position 15 in [D15A]SIIIA-
(2–20) produced a 10-fold increased affinity at Nav1.2 without
affecting Nav1.4 affinity, resulting in 70-fold neuronal selectiv-
ity. This enhanced affinity was lost if Asp-15 was replaced with
a positive charge (e.g. lysine) or an aromatic residue (e.g. tyro-
sine). The double mutant [K11R/D15A]SIIIA-(2–20) had a
similar potency and slightly enhanced Nav1.2 selectivity com-
pared with [D15A]SIIIA-(2–20), indicating that the lysine in
loop 2 of SIIIA can be interchanged with arginine without loss
of affinity.
Of the mutants tested, [H16A]SIIIA-(2–20) showed the
largest drop in affinity at both Nav1.2 and Nav1.4, confirming
the results reported for KIIIA (20). Interestingly, the double
mutant [D15A/H16R]SIIIA-(2–20) where the negative
charge from Asp was removed and an adjacent positive
charge was introduced, had similar affinity at Nav1.2 but a
30-fold loss of affinity at Nav1.4 compared with SIIIA-(2–
20), making it the most neuronally selective -conotoxin
identified in this study (137-fold selective). In contrast, the
corresponding Asp-16 analogue [D15A/H16D]SIIIA-(2–20)
had dramatically (100,000-fold) reduced affinity at Nav1.2
and 400-fold reduced affinity at Nav1.4, compared with
native SIIIA-(2–20), producing a Nav1.4-selective peptide.
The C-terminal arginine analogue [R18A]SIIIA-(2–20)
had  30-fold reduced affinity for Nav1.2 compared with
SIIIA(2–20) and  500-fold reduced affinity for Nav1.4 to
yield a second neuronally (116-fold) selective peptide. As
anticipated, [A11,A14,A15,D16,A18]SIIIA-(2–20), [A11,A-
14,A15,Y16,A18]SIIIA-(2–20), and [A11,A14,A15,A18]SIII-
A-(2–20) had significantly reduced affinity compared with
SIIIA-(2–20), particularly at Nav1.2.
To identify the structural determinants underlying these
shifts in affinity and selectivity, the three-dimensional solution
structure of SIIIA was calculated using 1H NMR spectroscopy.
In addition, H chemical shifts were determined to establish
that each analogue adopted the native fold found in SIIIA.
1H NMR Spectroscopy—Apart from TIIIA, spectral assign-
ment and structure calculations have proved difficult for
-conotoxins due to Pro/Hyp cis/trans isomerization that
produces line-broadening and multiple conformations (14,
26, 27). Consistent with the absence of Pro/Hyp residues in
SIIIA, NMR data indicated that a single conformation for
SIIIA and analogues dominated in solution. Only
[H16A]SIIIA-(2–20) showed a significant change in back-
bone H-chemical shift, indicating that His-16 provides
structural stabilization, especially to the C-terminal-half of
the peptide (Fig. 5). Interestingly, [A15,R16]SIIIA-(2–20)
and [A11,A14,A15,Y16,A18]SIIIA-(2–20) did not show a
change in secondary H-chemical shifts, apart from minor
local shifts at residue 15 or 11, respectively, suggesting that
arginine and tyrosine (but not Ala) can replace His-16 as a
structural stabilizer. The three-dimensional SIIIA structure
is described below.
SIIIA was examined by NMR
spectroscopy under aqueous condi-
tions over a range of different tem-
peratures to confirm proton assign-
ments (data not shown). NMR
solution structures were then calcu-
lated based on a total of 288 distance
restraints derived from 102 intra-
residue, 93 sequential, 89 medium-
and long-range NOEs, 4 hydrogen
bond restraints defining 2 hydrogen
bonds, and 12 and one 1 dihedral
angle restraints. A total of 46 of 50
structures converged to a consensus
structure. These structures con-
FIGURE 4.Affinity and selectivity of SIIIA, SIIIB and analogues at rat brain
(Nav1.2) and rat skeletal muscle (Nav1.4) VGSCs. The IC50 values to dis-
place 125I-TIIIA at rat brain and skeletal muscle membrane (mean S.E.) are
shown. The dotted line indicates SIIIA-(2–20) neuronal affinity. n 	 2–10
experiments each performed in triplicate, except those without error bars,
which were obtained from a single experiment.
FIGURE 5. Secondary H shifts (, ppm) for SIIIA, SIIIA-(2–20) and selected SIIIA-(2–20) analogues. A signifi-
cant change inbackbone structurewas seen for [A16]SIIIA-(2–20),while the [A11,A14,A15,Y16,A18]SIIIA-(2–20) and
[A11,A14,A15,A18]SIIIA-(2–20) analogues had secondary H shifts similar to native SIIIA and SIIIA-(2–20).
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tained 2 NOE violations greater than 0.2 Å and no dihedral
violations greater than 3°. The local and medium range NMR
data that provide information on the secondary structure of
SIIIA are given in supplemental Fig. S1A. The presence of sev-
eral H-NHi2, NH-NHi2, H-NHi3, and H-NHi3 NOEs
suggested the presence of several turns, and identified that a
helical secondary structure existed across residues 11–16. This
-helical motif was supported by a number of i-i3 and i-i4
NOEs and the presence of small 3JHN-H dihedral angles and
negative secondary H-chemical shifts in this region of the
peptide (Fig. 5).
The 17 lowest energy structures
of SIIIA are superimposed globally
in Fig. 6A, and a representative rib-
bon structure highlighting second-
ary structuralmotifs is shown in Fig.
6B. Overall, the structures are well-
defined with a backbone rootmean-
square deviation (RMSD) of 0.21
across residues 3–20 and 0.35 across
residue 1–20. The angular order
parameters for  and 	 angles are
also well ordered and 0.92 across
residues 6–20. The slightly disor-
dered N-terminal residues do not
appear to arise from conformational
exchange or structural flexibility,
because no line-broadening was
observed for these residues, and are
more likely due to a lack of NOEs to
loop 1, which contains two Gly res-
idues. Unlike the longer loop 1 in
other -conotoxins, which pro-
trudes outward, loop 1 of SIIIA
comprises a tightly folded -turn-
likemotif that is positioned to inter-
act with loop 3 (see Fig. 7). Analysis
of the surface exposure of each res-
idue illustrates this structural shift,
with loop 1 and the first two resi-
dues in loop 2 of SIIIA being rela-
tively buried compared with the
equivalent region of TIIIA (15),
whereas Lys-11, Trp-12, Arg-14
within the-helical region, together
with Arg-18, are relatively exposed
to solvent (supplemental Fig. S1B).
As expected, all Cys residues are
buried in the core of the molecule.
Comparing the NMR structures of
SIIIA and TIIIA reveals that the key
binding determinants of SIIIA are
distributed across the -helical
motif (Lys-11, Trp-12, Arg-14), and
Arg-18 with each contributing sim-
ilarly to affinity, whereas a single
arginine (Arg-14) is the key deter-
minant of TIIIA affinity (Fig. 7). In
supplemental Fig. S2, these comparisons are extended to PIIIA,
GIIIA, and SmIIIA.
DISCUSSION
The venoms of cone snails provide a rich source of -cono-
toxin inhibitors of VGSCs, including several recently isolated
-conotoxins with a smaller loop 2 (18, 19). In this study we
used assay-directed fractionation of milked C. striatus venom
to identify a new -conotoxin SIIIB, together with the recently
reported SIIIA (18) and TIIIA (15). Interestingly, the smaller
-conotoxins from C. striatus exploit a new pharmacophore
FIGURE 6. Three-dimensional NMR structure of SIIIA. A, SIIIA backbone superimposed over region 3–20 for
the 17 lowest energy structures. Shown are Lys-11, Arg-14, and Arg-18 (blue), Trp-12 (purple), and His-16 (red),
which influenced affinity at VGSCs. B, ribbon representation of the average structure of SIIIA showing the
-helical motif across residues 11–16. Disulfide bonds are shown in orange.
FIGURE 7. Comparison of -conotoxin SIIIA and TIIIA NMR structures. Representative ribbon structures of
(A) SIIIA and (B) TIIIA (15), superimposed across residues 8–13 (SIIIA) and 11–16 (TIIIA) to highlight the different
orientations of loop 1. Residues influencing VGSC affinity are indicated. Arg-14 is critical for high affinity
interactionsof TIIIA, andother larger-conotoxins (see supplemental Fig. S2),while Lys-11, Trp-12, Arg-14, and
Arg-18 contribute similarly to SIIIA affinity. His-16 in SIIIA appeared to affect VGSC affinity by perturbing backbone
structure. Disulfide bonds are shown in orange. See BMRB accession codes 20024 (TIIIA) and 20025 (SIIIA).
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that allows the development of peptides with selectivity for
Nav1.2 and potentially other TTX-S subtypes.
SIIIA and SIIIB both displaced 125I-TIIIA and [3H]STXbind-
ing to rat brain (Nav1.2) and rat skeletal muscle membrane
(Nav1.4), indicating they act at site 1 of the VGSC like the larger
-conotoxins PIIIA (24), TIIIA (15), GIIIA, and GIIIB (38).
SIIIA also inhibited current through oocyte-expressed Nav1.2
andNav1.4 at nanomolar potencies, confirming it acts as a pore
blocker of mammalian VGSCs. Like KIIIA (20), inhibition of
Nav1.2 was not reversed by toxin washout. SIIIA also inhibited
current through Nav1.3 at higher concentrations, showing that
these smaller -conotoxins have the potential to target addi-
tional neuronal subtypes. -Conotoxins SIIIA, KIIIA, SmIIIA,
CnIIIA, and CIIIA all potently inhibit frog TTX-R sodium ion
current (18, 21). However, we were unable to detect any inhibi-
tion of TTX-R or TTX-S sodium ion current in rat DRG neu-
rons by SIIIA, in contrast to an earlier study showing inhibition
of theTTX-R current in adult ratDRGbySIIIA (19). The inabil-
ity of SIIIA to inhibit TTX-S sodium ion current in neonatal rat
DRG indicates that Nav1.2 and 1.3 are not expressed at signifi-
cant levels in these neurons.
Anumber of analogues of SIIIA and SIIIB, and the neuronally
selective truncated SIIIA-(2–20), were synthesized to identify
residues contributing to VGSC affinity and selectivity. A loop 2
lysine is present in SIIIA and SIIIB instead of the corresponding
arginine previously found to be critical for high affinity interac-
tions of the larger -conotoxins GIIIA (39–41), PIIIA (24),
SmIIIA (17), and TIIIA (15). However, the [K11A]SIIIA-(2–20)
analogue revealed that this loop 2 lysine contributes only mod-
estly to VGSC affinity, producing a 6-fold reduction in affinity
for Nav1.2 or Nav1.4 compared with SIIIA-(2–20). Additional
SIIIA analogues [W12A]SIIIA-(2–20), [K14A]SIIIA-(2–20),
and [R18A]SIIIA-(2–20) revealed that Trp-12, Lys-14, and
Lys-18 also contribute significantly to affinity at Nav1.4 and to a
lesser extent Nav1.2 affinity. The single mutant [D15A]SIIIA-
(2–20) had enhanced affinity for Nav1.2 and unchanged Nav1.4
affinity, making it one of the most selective SIIIA analogues
identified. However, other substitutions (e.g. Tyr-15 or Lys-15)
were not well tolerated, showing that a small hydrophobic side
chain is preferred at position 15 in SIIIA. An alanine scan of
KIIIA revealed that the corresponding Trp-8, Arg-10, and
Arg-14 also contributed to Nav1.2 affinity, with Lys-7 and
Asp-11 contributing only to Nav1.4 affinity (20). Thus, the
pharmacophore for the smaller -conotoxins SIIIA and KIIIA
are similar, with residues important for the high affinity of SIIIA
at VGSCs located along the -helical motif plus Arg-18 (Fig. 6).
In comparison, the pharmacophore of larger -conotoxins
includingTIIIA is dominated by an arginine in loop 2 (Fig. 7 and
supplemental Fig. S2).
Replacing His-16 with alanine also had a dramatic effect on
SIIIA and KIIIA (20) affinity. However, H-chemical shift
changes indicated that this altered affinity arises, at least in part,
from changes in structure of the C-terminal half of the peptide
that potentially disrupt the -helix and thus the orientations of
themajor binding determinants required for high affinity inter-
actions at VGSCs. Interestingly, the potent and Nav1.2-selec-
tive [D15A/H16R]SIIIA-(2–20) did not show a change in sec-
ondary H-chemical shifts, apart from minor local shifts at
residue 15, indicating that Arg-16 might play a similar struc-
tural role to His-16.
Comparing the NMR solution structure of SIIIA with TIIIA
it is apparent they adopt distinct conformations in solution (Fig.
7). Superimposition of loop 2 residues 8–13 of SIIIA with the
corresponding residues 11–16 of TIIIA andPIIIA and gave high
RMSDs of 1.08 1.53, respectively. This affect is even more dra-
matic when SIIIA and SmIIIA are compared across loops 2 and
3 (RMSD of 2.58), despite having almost identical sequences. In
contrast, comparing the same residues between PIIIA and
TIIIA gave a lower RMSD of 0.64. Examining the secondary
structures of the different -conotoxins provides an explana-
tion. GIIIA, GIIIB, PIIIA, SmIIIA, and TIIIA each comprise a
series of turns and loops (14, 15, 17, 25, 27, 42), with a-hairpin
seen in the N-terminal part of GIIIA and GIIIB and the minor
conformation of PIIIA (14). These turns in GIIIB, SmIIIA,
PIIIA, and TIIIA produce a 310-helix across residues 13–22,
13–20, 13–17, and 12–15, respectively (numbering specific to
each conotoxin) (14, 15, 17, 25, 27, 42) comparedwith the-he-
lix found in SIIIA. Previously described structures of SIIIA and
KIIIA (18, 20, 21), as well as CnIIIA, CnIIIB, CIIIA, and MIIIA
(21), were modeled from the NMR structure of SmIIIA (17).
However, the NMR solution structures of SIIIA reveals that
loop 1 of SIIIA is not extended as seen inTIIIA (Fig. 7) and other
larger -conotoxins (supplemental Fig. S2) but instead folds in
toward the -helical region. This altered conformation, sup-
ported by a series of long-range NOEs between loops 1 and 3,
within loops 2 and 3, and between loops 2 and 3, permits amore
extended C-terminal region not seen in the larger -conotox-
ins. Interestingly, these structural shifts allow Lys-11, Arg-14,
and Arg-18 of SIIIA and Arg-14, Arg-17, and Lys-6 of TIIIA to
adopt similar relative positions (Fig. 7) thatmight allow binding
to a negatively charged crevice in or near the mouth of the
VGSC. A comparison of the sequences of KIIIA, SIIIA, and
SIIIB reveals they are similar across loops 2 and 3, and include
all important binding determinants, suggesting they likely have
similar binding modes and similar conformations in solution.
The present study of SIIIA and SIIIB extends our knowledge
of the structure-activity relationship of smaller -conotoxins
and defines key residues contributing to Nav1.2 selectivity.
SIIIA contains an -helix across residues 11–16 unlike previ-
ously determined-conotoxin NMR structures. The reduction
in size of loop 1 from five residues in the larger-conotoxins to
three in smaller -conotoxins like SIIIA appears to underlie a
shift from a 310-helical motif to the -helix. SIIIA targets
Nav1.2, 1.3, and 1.4, whereas the even smaller KIIIA addition-
ally targets Nav1.1, 1.6, and 1.7 (20), indicating that the size of
loop 1 can influence not only the structure but also the selec-
tivity of -conotoxins. The range of VGSC subtypes inhibited
by these smaller -conotoxins opens the door to the develop-
ment of peptides with novel subtype specificity and analgesic
potential.
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